What is ADMA Biologics's market cap?

ADMA Biologics (ADMA) has a market capitalization of $2.0B and trades on NASDAQ.

What is ADMA Biologics's revenue and profitability?

ADMA Biologics generated $509.9M in trailing twelve-month revenue with net income of $165.4M, representing a net margin of 32.4%. Gross margin stands at 61.3%, with free cash flow of $107.9M. These figures are based on the Q1 2026 filing.

Who are ADMA Biologics's competitors?

ADMA Biologics's key competitors include Acumen Pharmaceuticals, Inc. Common Stock, Lifecore Biomedical, Inc. Common Stock, AbCellera Biologics Inc. Common Shares, and others. These companies compete in similar markets and product categories.

Who does ADMA Biologics partner with?

ADMA Biologics's notable partners include Grifols Worldwide Operations Limited, KEDPlasma LLC, Biotest AG, and others.

What subsidiaries does ADMA Biologics have?

ADMA Biologics's subsidiaries include ADMA BioManufacturing, LLC, ADMA BioCenters Georgia Inc., ADMA Plasma Biologics, Inc..

Where is ADMA Biologics headquartered?

ADMA Biologics is headquartered in United States of America and employs approximately 624 people. It has been publicly traded since 2013.

ADMA Biologics

ADMA

ADMA Biologics is a vertically integrated biopharmaceutical company focused on the manufacturing and commercialization of specialty plasma-derived biologics.

Market cap

$1.97B-55.7%

Revenue$509.9M+11.0%

Net income$165.4M-20.0%

Free cash flow$107.9M+19.1%

EPS (diluted)$0.68-20.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$114.5MMiss by $25.5M EPS$0.19Miss by $0.00

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$125.3M

EPS estimate$0.16

Financials

Q1 2026

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation & ratios

Valuation

See full

Market cap$1.97B-55.7%

Enterprise value$2.03B-51.8%

P/E11.9×-8.7×

P/S3.9×-5.2×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Segments

By product

See full

ASCENIV$97.5M+27.7%

BIVIGAM$15.4M-54.0%

Intermediates And Other$833.0K-78.5%

By segment

See full

ADMA Bio Manufacturing$113.7M0.0%

Plasma Collection Centers$716.0K-31.8%

Competitors

By market cap

ADMA Biologics$2.0B-54.3%

AbCellera Biologics Inc.$1.6B+9.2%

AnaptysBio, Inc.$1.6B+103%

DiaMedica Therapeutics$363.2M+39.4%

MacroGenics$254.3M+141%

Lifecore Biomedical, Inc.$162.8M-40.0%

Acumen Pharmaceuticals, Inc.$158.9M+79.7%

Adicet Bio, Inc.$75.3M+21.1%

By revenue growth

AbCellera Biologics Inc.+243%

AnaptysBio, Inc.+108%

ADMA Biologics+11.0%

Lifecore Biomedical, Inc.-3.8%

By net margin

ADMA Biologics32.43%-12.6pp

Lifecore Biomedical, Inc.-30.04%-37.9pp

AnaptysBio, Inc.-49.94%+80.0pp

AbCellera Biologics Inc.-181.75%+544pp

Profile

ADMA Biologics is a vertically integrated biopharmaceutical company focused on the manufacturing and commercialization of specialty plasma-derived biologics. The company provides end-to-end solutions for immunodeficient patients at risk of infection by managing the entire value chain from plasma collection to final product distribution. Its core value proposition lies in its proprietary fractionation processes and donor screening technologies that produce high-titer hyperimmune globulins.

Competitive position

A vertically integrated player in the U.S. plasma market with proprietary high-titer screening assays and a specialized focus on hyperimmune globulins.

GeographiesUnited States, Europe, Middle East, Northern Africa

Customer segmentsImmunodeficient patients, Specialty healthcare providers, Pharmaceutical manufacturers

Business modelManufacturing, Direct-to-specialist sales, Vertical integration

SuppliersHuman plasma donors, Third-party plasma collection centers, Specialized medical devices for plasmapheresis, Aseptic filling machine manufacturers

CustomersDrug wholesalers, Independent distributors, Specialty pharmacies, Acute and ambulatory infusion centers

CountryUnited States of America

Listed2013

Employees624.0

CEOAdam S. Grossman

SectorHealthcare

IndustryBiotechnology

Websiteadmabiologics.com

FilingsSEC EDGAR

Ask your AI about ADMA Biologics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's market cap?: ADMA Biologics (ADMA) has a market capitalization of $2.0B and trades on NASDAQ.
What is ADMA Biologics's revenue and profitability?: ADMA Biologics generated $509.9M in trailing twelve-month revenue with net income of $165.4M, representing a net margin of 32.4%. Gross margin stands at 61.3%, with free cash flow of $107.9M. These figures are based on the Q1 2026 filing.
Who are ADMA Biologics's competitors?: ADMA Biologics's key competitors include Acumen Pharmaceuticals, Inc. Common Stock, Lifecore Biomedical, Inc. Common Stock, AbCellera Biologics Inc. Common Shares, and others. These companies compete in similar markets and product categories.
Who does ADMA Biologics partner with?: ADMA Biologics's notable partners include Grifols Worldwide Operations Limited, KEDPlasma LLC, Biotest AG, and others.
What subsidiaries does ADMA Biologics have?: ADMA Biologics's subsidiaries include ADMA BioManufacturing, LLC, ADMA BioCenters Georgia Inc., ADMA Plasma Biologics, Inc..
Where is ADMA Biologics headquartered?: ADMA Biologics is headquartered in United States of America and employs approximately 624 people. It has been publicly traded since 2013.